WO2021112242A1 - ステロイド化合物およびオロパタジンを含有する医薬組成物 - Google Patents
ステロイド化合物およびオロパタジンを含有する医薬組成物 Download PDFInfo
- Publication number
- WO2021112242A1 WO2021112242A1 PCT/JP2020/045314 JP2020045314W WO2021112242A1 WO 2021112242 A1 WO2021112242 A1 WO 2021112242A1 JP 2020045314 W JP2020045314 W JP 2020045314W WO 2021112242 A1 WO2021112242 A1 WO 2021112242A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- olopatadine
- weight
- steroid compound
- Prior art date
Links
- 0 *C=C1c2cc(*)ccc2OCC2C=CC=C[C@@]12 Chemical compound *C=C1c2cc(*)ccc2OCC2C=CC=C[C@@]12 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Definitions
- the present invention relates to a uniform composition containing a steroid compound and olopatadine, in which the steroid compound is stably present in a suspended state and olopatadine is in a dissolved state, and a method for producing the same.
- the present invention can also be used for the treatment of allergic rhinitis.
- Steroid compounds with anti-inflammatory activity are widely used in the treatment of inflammatory diseases such as dermatitis, asthma and rhinitis.
- beclomethasone propionate, fluticasone propionate, mometasone furancarboxylic acid ester and fluticasone furancarboxylic acid ester which are a type of steroid compound, are glucocorticoids used topically to reduce skin or airway inflammation. It is a steroid compound and is already commercially available as a nasal spray for allergic rhinitis (Patent Document 1).
- steroid compounds are extremely sparingly soluble in water, and when prepared as nasal drops for the treatment of allergic rhinitis, they are irritating considering that they are administered to the delicate nasal mucosa. It is difficult to contain a large amount of organic solvent for the purpose of dissolving olopatadine, and even if other solubilizers are considered, there are certain restrictions on the selection of safe solubilizers with less mucosal irritation.
- some nasal drops have been developed as an aqueous suspension in a weakly acidic region of pH 4.5 to 6.5 and are already on the market.
- olopatadine has already been used as an antihistamine for the treatment of allergic rhinitis and allergic conjunctivitis
- Patent Documents 2 and 3 disclose nasal drops of its hydrochloride, specifically.
- Allergic or inflammatory disorders of the nose Disclosed are inventions relating to topical formulations used to treat and / or prevent.
- PATANASE registered trademark
- olopatadine hydrochloride nasal solution 0.6% is currently the only olopatadine nasal drop product commercially available for nasal use.
- olopatazine hydrochloride equivalent to 0.6% olopatazine, 0.01% benzalconium chloride, and non-specific amounts of sodium dibasic phosphate, sodium edetate hydrate, sodium chloride.
- Hydrochloric acid and / or sodium hydroxide for pH regulation
- purified water but the pH is regulated to about 3.7, which is quite irritating to the intranasal mucosa.
- PATANASE registered trademark
- PATANOL registered trademark
- the present invention prepares a nasal drop composition as a mixture of olopatadine and a steroid compound, and has a physiologically mild and suitable pH of 4.0 to 7.0, preferably 4.5 to 6.5, more preferably.
- aqueous spray nasal drops in which steroid compounds are present in a stable suspension and olopatadine in a dissolved state even at higher concentrations in the 5.0-6.0 range. The purpose is.
- carboxyvinyl which is not a usual dissolving agent or solubilizing agent, and is not a suspending agent, is added to a nasal drop composition containing a steroid compound and olopatadine.
- carboxyvinyl which is not a usual dissolving agent or solubilizing agent, and is not a suspending agent.
- Item 5 The pharmaceutical composition according to any one of Items 1 to 3, which is adjusted to 5.5, more preferably 5.0 to 6.0).
- Olopatadine or a pharmaceutically acceptable salt thereof is olopatadine hydrochloride, the concentration of olopatadine hydrochloride is 0.2% (weight / weight) or more, and olopatadine is present in a dissolved state in the composition.
- Item 8 The pharmaceutical composition according to any one of Items 1 to 4.
- Item 6 The medicament according to any one of Items 1 to 5, wherein the steroid compound has a concentration of 0.005 to 1% (weight / weight), and the steroid compound is present in a stable dispersed state in the composition. Composition.
- Item 7 The pharmaceutical composition according to any one of Items 1 to 6, wherein the steroid compound is any one of beclomethasone propionate, fluticasone propionate, mometasone furancarboxylic acid ester, or fluticasone furancarboxylic acid ester. Stuff.
- Item 13 The pharmaceutical composition according to Item 12, wherein the suspending agent contains polysorbate 80.
- Item 17 The pharmaceutical composition according to Item 16, wherein the stabilizer comprises sodium edetate hydrate.
- Item 19 The pharmaceutical composition according to Item 18, wherein the tonicity agent comprises sodium chloride and / or glycerin.
- Item 20 The pharmaceutical composition according to Item 18 or 19, wherein the tonicity agent is present at a concentration of 0.1 to 10% (weight / weight).
- Item 22 The pharmaceutical composition according to any one of Items 1 to 21, which has a viscosity of 250 to 2500 mPa ⁇ s (preferably 500 to 1500 mPa ⁇ s).
- the pH regulator is sodium hydroxide
- the neutralizer is L-arginine
- the suspending agent is polysorbate 80
- the preservative is benzalkonium chloride
- the stabilizer is sodium edetate hydrate.
- the pharmaceutical composition according to any one of Items 21 to 23, wherein the tonicity agent is glycerin and sodium chloride.
- Item 25 The pharmaceutical composition according to any one of Items 1 to 24, wherein the pharmaceutical composition is an aqueous solution for nasal drops.
- a method of dissolving olopatadine in the pH range of 5.0 to 6.0 by adding a carboxyvinyl polymer and an aqueous suspension containing a fluticasone furancarboxylic acid ester are prepared using a method of stabilizing suspension at the same time.
- olopatadine is dissolved in a spray-type nasal spray as an aqueous suspension containing olopatadine or a pharmaceutically acceptable salt thereof, and a steroid compound, and the suspension of the steroid compound is extremely stabilized. , No need to shake before use.
- the pH of the drug is adjusted to 5.0 to 6.0, which is more physiologically acceptable as a nasal spray, and after the drug is sprayed into the nasal cavity, it becomes easier to stay in the nasal cavity, which is long-lasting and effective in terms of drug efficacy. Improvement can be expected.
- the steroid compound is not particularly limited as long as it is a steroid compound having an anti-inflammatory effect, and examples thereof include beclomethasone propionate, fluticasone propionate, mometasone furancarboxylic acid ester, and fluticasone furancarboxylic acid ester, and fluticasone furan.
- a carboxylic acid ester is preferred.
- Fluticasone furancarboxylic acid ester is furan-2-carboxylic acid 6 ⁇ , 9-difluoro-17 ⁇ -[(fluoromethylsulfanyl) carbonyl] -11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta-1,4-diene- It is a 17 ⁇ -yl ester, has the following structure, and is widely used for the treatment of allergic rhinitis.
- the concentration of the steroid compound contained in the formulation of the present invention is 0.005 to 1% (weight / weight), preferably 0.01 to 0.1%.
- Olopatadine is the formula: It is a compound having the above structure and has already been used as an antihistamine for the treatment of allergic rhinitis and allergic conjunctivitis.
- olopatadine a composition for nasal drops is prepared using olopatadine or a salt thereof at the time of preparation, and olopatadine hydrochloride is preferably used.
- concentration of olopatadine contained in the formulation of the present invention is 0.2% (weight / weight) or more, preferably 0.4 to 0.8% (weight / weight), more preferably 0.4 as olopatadine hydrochloride. ⁇ 0.7% (weight / weight).
- the "pharmaceutically acceptable salt” is not particularly limited as long as it does not have an adverse effect such as toxicity when used in humans and animals, and the acid addition salt includes hydrochloride, citrate, succinic acid, etc. Hydrobromide, ascorbate, flotaide, sulfate, acetate, valerate, oleate, palmitate, laurate, stearate, bicarbonate, borate, benzoic acid
- Examples include salts, lactic acid, phosphates, methanesulfonates, p-toluenesulfonates, oxalates, maleic acid, fumaric acid, tartrates, glucoheptonic acid, lactobionates and lauryl sulfates.
- the salt of the above include alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as calcium and magnesium.
- composition of the present invention can be formulated, for example, for oral administration, parenteral administration or topical administration, particularly for topical administration.
- Topical administration as used herein includes administration by application, insufflation and inhalation.
- formulations for topical administration include ointments, lotions, creams, gels, sprays, aerosols, suppositories, eye drops, ear drops, nasal drops, intranasal spray formulations and the like.
- a nasal drop composition for local administration into the nasal cavity there are a nasal drop agent, an intranasal administration type spray preparation, and the like.
- the "composition for nasal drops” is an aqueous solution for nasal drops and is in a suspended state.
- the carboxyvinyl polymer is not particularly limited as long as it is used in a normal preparation.
- the carboxyvinyl polymer is preferably one in which a shearing force is applied from the outside to adjust the viscosity, and the method and effect thereof are described in WO 2007/123193.
- a known shearing force such as a high-speed rotary emulsifying device, a colloid mill type emulsifying device, a high-pressure emulsifying device, a roll mill type emulsifying device, an ultrasonic emulsifying device, and a membrane emulsifying device. it can.
- a homomixer type, a comb tooth type, and an intermittent jet flow generating type high-speed rotary emulsifying device are preferable.
- the concentration of the carboxyvinyl polymer is 0.1 to 2% (weight / weight), preferably 0.25 to 1.0%.
- suspending agent used in the present invention examples include polysorbate 80, polyoxyl 40 stearate, and / or polyoxyethylene hydrogenated castor oil 60, and polysorbate 80 is preferable.
- concentration of the suspending agent is 0.01 to 1% (weight / weight), preferably 0.025 to 0.5%.
- Examples of the preservative used in the present invention include benzalkonium chloride, benzethonium chloride, and chlorobutanol, and benzalkonium chloride is preferable.
- the concentration of the preservative is 0.005 to 1% (weight / weight), preferably 0.01 to 0.1%, respectively.
- the stabilizer used in the present invention examples include sodium edetate hydrate.
- the concentration of the stabilizer is 0.005 to 1% (weight / weight), preferably 0.01 to 0.1%, respectively.
- the aqueous nasal drop composition of the present invention is preferably isotonic or near isotonic.
- Isotonic agents such as sodium chloride, boric acid, glycerin and / or glucose are used to adjust the isotonicity.
- concentration of the tonicity agent is 0.1 to 10% (weight / weight), preferably 0.1 to 1.0%, respectively.
- the pH of the aqueous nasal drops composition of the present invention needs to be adjusted to 4.0 to 7.0 (preferably 4.5 to 6.5, more preferably 5.0 to 6.0).
- 4.0 to 7.0 preferably 4.5 to 6.5, more preferably 5.0 to 6.0.
- sodium hydroxide, potassium hydroxide, hydrochloric acid or the like is used as the pH adjusting agent, and sodium hydroxide is preferably used.
- the pH of the present invention is adjusted by using L-arginine as a neutralizing agent.
- the viscosity of the aqueous nasal drop composition of the present invention is usually 250 to 2500 mPa ⁇ s, preferably 500 to 1500 mPa ⁇ s.
- the "dissolved state” means a state in which the target pharmaceutical component is completely dissolved
- the “dispersed state” means a state in which the target pharmaceutical component does not precipitate crystals and is uniformly suspended.
- the droplet diameter of the aqueous nasal drop composition of the present invention refers to the particle diameter of the droplet when sprayed, and the average droplet diameter thereof is preferably 30 to 100 ⁇ m, more preferably 40 to 80 ⁇ m. is there.
- Form nasal drops refers to those for spraying into the nasal cavity with a device such as a spray type, and "composition for nasal drops” means a liquid preparation for spraying into the nasal cavity for administration.
- composition for nasal drops means a liquid preparation for spraying into the nasal cavity for administration.
- the viscosity was measured by the Japanese Pharmacopoeia, general test method, viscosity measurement method, rotational viscometer method, and the details of the measurement method are as follows.
- ⁇ Measuring method Place 1.1 mL of the test sample (test product) in a sample cup of a cone-plate type rotational viscometer (cone plate type) set at 20 ° C in advance so as not to contain air bubbles, and leave it for 5 minutes, and then the following conditions. The viscosity value when the shearing force was applied for 3 minutes was measured.
- ⁇ Measurement condition Equipment used: Toki Sangyo Co., Ltd.
- the droplet particle size (average droplet diameter, 10 to 100 ⁇ m (%)) was measured using a laser diffraction type particle size distribution measuring device. ⁇ Measurement condition ⁇ Equipment used: Malvern Spray Tech Reading distance: 30 mm Injection angle: 40 ° Extrusion speed: 100 mm / s
- Example 1 (Prescription) (Production method) After dissolving L-arginine, sodium edetate hydrate and olopatadine hydrochloride in purified water, the mixed solution is put into a vacuum stirrer, and benzalconium chloride and half the amount of polysorbate 80 are further added to purified water. The dissolved solution was added, and the mixture was mixed and stirred. A solution prepared by mixing and dissolving a carboxyvinyl polymer in purified water was added thereto. They were mixed and stirred in a vacuum stirrer.
- fluticazone furancarboxylic acid ester was moistened with concentrated glycerin, the other half of polysorbate 80 and purified water were added thereto, and the mixture was sufficiently stirred, poured into the above stirring mixture, and mixed and stirred in a vacuum stirring device. .. If necessary, the pH was adjusted to 5.5 with a sodium hydroxide solution or dilute hydrochloric acid, and then shearing was added at a higher speed, and the mixture was mixed and stirred until the viscosity became 1000 mPa ⁇ s to obtain a uniform nasal drop composition.
- Example 2 (prescription) (Production method) After dissolving L-arginine, sodium edetate hydrate and olopatadine hydrochloride in purified water, the mixed solution is put into a vacuum stirrer, and benzalconium chloride and half the amount of polysorbate 80 are further added to purified water. The dissolved solution was added, and the mixture was mixed and stirred. A solution prepared by mixing and dissolving a carboxyvinyl polymer in purified water was added thereto. They were mixed and stirred in a vacuum stirrer.
- fluticazone furancarboxylic acid ester was moistened with concentrated glycerin, the other half of polysorbate 80 and purified water were added thereto, and the mixture was sufficiently stirred, poured into the above stirring mixture, and mixed and stirred in a vacuum stirring device. .. If necessary, the pH was adjusted to 5.5 with a sodium hydroxide solution or dilute hydrochloric acid, and then shearing was added at a higher speed, and the mixture was mixed and stirred until the viscosity became 1250 mPa ⁇ s to obtain a uniform nasal drop composition.
- Example 3 (Prescription) (Production method) After dissolving L-arginine, sodium edetate hydrate and olopatadine hydrochloride in purified water, the mixed solution is put into a vacuum stirrer, and benzalconium chloride and half the amount of polysorbate 80 are further added to purified water. The dissolved solution was added, and the mixture was mixed and stirred. A solution prepared by mixing and dissolving a carboxyvinyl polymer in purified water was added thereto. They were mixed and stirred in a vacuum stirrer.
- fluticazone furancarboxylic acid ester was moistened with concentrated glycerin, the other half of polysorbate 80 and purified water were added thereto, and the mixture was sufficiently stirred, poured into the above stirring mixture, and mixed and stirred in a vacuum stirring device. .. If necessary, adjust the pH to 5.5 with sodium hydroxide solution or dilute hydrochloric acid, add shear at a higher speed, mix and stir until the viscosity reaches 1000 mPa ⁇ s, and finally add ethanol, mix and stir to make it uniform.
- the nasal drop composition was prepared.
- Example 4 (Prescription) (Production method) After dissolving L-arginine, sodium edetate hydrate and olopatadine hydrochloride in purified water, the mixed solution is put into a vacuum stirrer, and benzalconium chloride and half the amount of polysorbate 80 are further added to purified water. The dissolved solution was added, and the mixture was mixed and stirred. A solution prepared by mixing and dissolving a carboxyvinyl polymer in purified water was added thereto. They were mixed and stirred in a vacuum stirrer.
- bechrometazone propionate was moistened with concentrated glycerin, the other half of polysorbate 80 and purified water were added thereto, and the mixture was sufficiently stirred, poured into the above stirring mixture, and mixed and stirred in a vacuum stirring device. If necessary, the pH was adjusted to pH 6.0 with a sodium hydroxide solution or dilute hydrochloric acid, and then shearing was added at a higher speed to mix and stir until the viscosity became 1500 mPa ⁇ s to obtain a uniform nasal drop composition.
- Example 5 (Prescription) (Production method) After dissolving L-arginine, sodium edetate hydrate and olopatadine hydrochloride in purified water, the mixed solution is put into a vacuum stirrer, and benzalconium chloride and half the amount of polysorbate 80 are further added to purified water. The dissolved solution was added, and the mixture was mixed and stirred. A solution prepared by mixing and dissolving a carboxyvinyl polymer in purified water was added thereto. They were mixed and stirred in a vacuum stirrer.
- fluticazone furancarboxylic acid ester was moistened with concentrated glycerin, the other half of polysorbate 80 and purified water were added thereto, and the mixture was sufficiently stirred, poured into the above stirring mixture, and mixed and stirred in a vacuum stirring device. .. If necessary, adjust the pH to 5.0 with sodium hydroxide solution or dilute hydrochloric acid, add shear at a higher speed, mix and stir until the viscosity reaches 1000 mPa ⁇ s, and finally add ethanol, mix and stir to make it uniform. The composition was nasal drops.
- Example 6 (Prescription) (Production method) After dissolving L-arginine, sodium edetate hydrate and olopatadine hydrochloride in purified water, the mixed solution is put into a vacuum stirrer, and benzalconium chloride and half the amount of polysorbate 80 are further added to purified water. The dissolved solution was added, and the mixture was mixed and stirred. A solution prepared by mixing and dissolving a carboxyvinyl polymer in purified water was added thereto. They were mixed and stirred in a vacuum stirrer.
- Comparative Example 1 [Example 1 described in Japanese Patent No. 4838493] (Prescription) * : Mixture of crystalline cellulose and sodium carboxymethyl cellulose (manufacturing method) Glucose was dissolved in purified water to prepare a glucose solution, and sodium edetate hydrate was dissolved therein, and then Avicel RC591 was added with stirring and hydrated to obtain suspension A. Separately, polysorbate 80 was dissolved in purified water at 50 to 60 ° C. to moisten the fluticasone furancarboxylic acid ester, and the other half of the polysorbate 80 and purified water were added thereto to prepare suspension B. Suspension A and suspension B were combined and stirred. Benzalkonium chloride dissolved in purified water was added thereto, and the mixture was stirred. After adjusting the pH to 6.0 with 1N hydrochloric acid, purified water was added to correct the weight.
- Comparative Example 2 [Additional combination of olopatadine hydrochloride to Example 1 described in Japanese Patent No. 4838493] (Prescription) * : Mixture of crystalline cellulose and sodium carboxymethyl cellulose (manufacturing method) Glucose was dissolved in purified water to prepare a glucose solution, and sodium edetate hydrate and olopatadine hydrochloride were dissolved therein, and then Avicel RC591 was added with stirring to hydrate the suspension A. Separately, polysorbate 80 was dissolved in purified water at 50 to 60 ° C. to moisten the fluticasone furancarboxylic acid ester, and the other half of the polysorbate 80 and purified water were added thereto to prepare suspension B. Suspension A and suspension B were combined and stirred, to which benzalkonium chloride dissolved in purified water was added and stirred. After adjusting the pH to 6.0 with 1N hydrochloric acid, purified water was added to correct the weight.
- Comparative Example 3 [Example 1 described in Japanese Patent No. 5149308] (Prescription) (Production method) Disodium hydrogen phosphate (anhydrous), sodium chloride, sodium edetate hydrate, benzalconium chloride and olopatadine hydrochloride were added with stirring of purified water. An appropriate amount of dilute hydrochloric acid was added for each appropriate time for dissolution of each component. After adding purified water, measuring the pH and adjusting to 3.7 with hydrochloric acid and sodium hydroxide as needed. Purified water was added to correct the weight.
- ⁇ No crystals other than steroids were confirmed, no precipitated crystals, and it was judged that olopatadine was dissolved.
- ⁇ In addition to steroids, precipitated crystals of 50 ⁇ m or more were confirmed, and it was determined that olopatadine was precipitated.
- Example 7 Comparative Example 4, Comparative Example 5, and Comparative Example 6.
- Test preparation Each test sample (test preparation) is sufficiently mixed and stirred, and the content of fluticasone furancarboxylic acid ester in each test sample is measured by high performance liquid chromatography while maintaining a uniform state, and the initial uniform state is completed (the initial uniform state is completed). Quantitative result A).
- 12 g of each test sample in a uniform state is filled in a 13.5 mL glass screw tube and shaken well again to obtain a uniform state. Separately, the test sample is centrifuged (5000 rpm, 10 minutes).
- olopatadine is stable as a pharmaceutical composition containing a steroid compound and an olopatadine free base or a pharmaceutically acceptable salt of an equivalent amount of olopatadine as a mixture at a physiologically acceptable pH, particularly as a nasal drop composition. Since it is dissolved and highly viscous, the suspension of the steroid compound is extremely stabilized, and it is no longer necessary to shake it before use. In addition, after the drug is sprayed into the nasal cavity, it becomes easier to stay in the nasal cavity, and continuous and effective improvement in terms of drug efficacy can be expected.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
[項15]防腐剤がベンザルコニウム塩化物を含む、項14の医薬組成物。
pH調節剤が水酸化ナトリウムであり、中和剤がL-アルギニンであり、懸濁剤がポリソルベート80であり、防腐剤がベンザルコニウム塩化物であり、安定化剤がエデト酸ナトリウム水和物であり、等張化剤がグリセリンおよび塩化ナトリウムである項21~23のいずれか1項に記載の医薬組成物。
項1~25のいずれか1項に記載の医薬組成物を含む、鼻腔内投与型スプレー用製剤。
カルボキシビニルポリマーを添加することによってオロパタジンをpH5.0~6.0の範囲で溶解する方法とフルチカゾンフランカルボン酸エステルを含む水性懸濁液を、懸濁性を安定化する方法を同時に用いて調製した医薬組成物。
本明細書で使用される局所投与には、塗布、送気および吸入などによる投与がある。局所投与用の製剤の例には、軟膏、ローション、クリーム、ゲル、噴霧剤、エアゾール剤、坐剤、点眼剤、点耳剤、点鼻剤、鼻腔内投与型スプレー製剤などがある。
特に、鼻腔内への局所投与用の点鼻用組成物として、点鼻剤、鼻腔内投与型スプレー用製剤などがある。ここで「点鼻用組成物」は、点鼻用水性液剤であり、懸濁状態を呈している。
本発明の鼻腔内投与型スプレー点鼻製剤は、通常の点鼻用スプレーや、WO 2007/123193、WO 2007/123207に記載されているような上方排圧エアレス式噴霧容器に充填されるような点鼻製剤を意図する。
〔測定方法〕
試験検体(被験製剤)1.1mLをなるべく気泡が入らないように、あらかじめ20℃に設定した円すい-平板形回転粘度計(コーンプレート型)のサンプルカップに入れ5分間放置した後、下記の条件で3分間剪断力を加えたときの粘度値を測定した。
〔測定条件〕
使用機器:東機産業株式会社 TVE-25形粘度計
測定レンジ:R(フルスケールトルク 1437.4μN・m)
剪断速度:9.575s-1(毎分2.5回転)
ローター:1°34’×R24
〔測定条件〕
使用機器:マルバーンスプレーテック
読み取り距離:30mm
噴射角度:40°
押し出しスピード:100mm/s
〔測定条件〕
使用機器:株式会社キーエンス デジタルマイクロスコープVHX-7000
倍率:500倍
(処方)
(製造方法)
精製水にL-アルギニン、エデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、その混合溶液を真空撹拌装置に投入し、更に精製水にベンザルコニウム塩化物及び半量のポリソルベート80を加えて溶解した液を加え、混合撹拌した。これにあらかじめカルボキシビニルポリマーを精製水に混合溶解した液を投入した。それらを真空撹拌装置内で混合撹拌した。別に、フルチカゾンフランカルボン酸エステルを濃グリセリンに湿らせ、そこに残り半量のポリソルベート80と精製水を加え、十分に撹拌し、先の撹拌混合液に投入しそれを真空撹拌装置内で混合撹拌した。必要があればpHを水酸化ナトリウム溶液または希塩酸でpH5.5に調節した後、更に高速で剪断を付加し粘度が1000mPa・sになるまで混合撹拌し、均一な点鼻組成物とした。
(製造方法)
精製水にL-アルギニン、エデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、その混合溶液を真空撹拌装置に投入し、更に精製水にベンザルコニウム塩化物及び半量のポリソルベート80を加えて溶解した液を加え、混合撹拌した。これにあらかじめカルボキシビニルポリマーを精製水に混合溶解した液を投入した。それらを真空撹拌装置内で混合撹拌した。別に、フルチカゾンフランカルボン酸エステルを濃グリセリンに湿らせ、そこに残り半量のポリソルベート80と精製水を加え、十分に撹拌し、先の撹拌混合液に投入しそれを真空撹拌装置内で混合撹拌した。必要があればpHを水酸化ナトリウム溶液または希塩酸でpH5.5に調節した後、更に高速で剪断を付加し粘度が1250mPa・sになるまで混合撹拌し、均一な点鼻組成物とした。
(処方)
(製造方法)
精製水にL-アルギニン、エデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、その混合溶液を真空撹拌装置に投入し、更に精製水にベンザルコニウム塩化物及び半量のポリソルベート80を加えて溶解した液を加え、混合撹拌した。これにあらかじめカルボキシビニルポリマーを精製水に混合溶解した液を投入した。それらを真空撹拌装置内で混合撹拌した。別に、フルチカゾンフランカルボン酸エステルを濃グリセリンに湿らせ、そこに残り半量のポリソルベート80と精製水を加え、十分に撹拌し、先の撹拌混合液に投入しそれを真空撹拌装置内で混合撹拌した。必要があればpHを水酸化ナトリウム溶液または希塩酸でpH5.5に調節した後、更に高速で剪断を付加し粘度が1000mPa・sになるまで混合撹拌し最後にエタノールを添加し、混合撹拌し均一な点鼻組成物とした。
(処方)
(製造方法)
精製水にL-アルギニン、エデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、その混合溶液を真空撹拌装置に投入し、更に精製水にベンザルコニウム塩化物及び半量のポリソルベート80を加えて溶解した液を加え、混合撹拌した。これにあらかじめカルボキシビニルポリマーを精製水に混合溶解した液を投入した。それらを真空撹拌装置内で混合撹拌した。別に、ベクロメタゾンプロピオン酸エステルを濃グリセリンに湿らせ、そこに残り半量のポリソルベート80と精製水を加え、十分に撹拌し、先の撹拌混合液に投入しそれを真空撹拌装置内で混合撹拌した。必要があればpHを水酸化ナトリウム溶液または希塩酸でpH6.0に調節した後、更に高速で剪断を付加し粘度が1500mPa・sになるまで混合撹拌し、均一な点鼻組成物とした。
(処方)
(製造方法)
精製水にL-アルギニン、エデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、その混合溶液を真空撹拌装置に投入し、更に精製水にベンザルコニウム塩化物及び半量のポリソルベート80を加えて溶解した液を加え、混合撹拌した。これにあらかじめカルボキシビニルポリマーを精製水に混合溶解した液を投入した。それらを真空撹拌装置内で混合撹拌した。別に、フルチカゾンフランカルボン酸エステルを濃グリセリンに湿らせ、そこに残り半量のポリソルベート80と精製水を加え、十分に撹拌し、先の撹拌混合液に投入しそれを真空撹拌装置内で混合撹拌した。必要があればpHを水酸化ナトリウム溶液または希塩酸でpH5.0に調節した後、更に高速で剪断を付加し粘度が1000mPa・sになるまで混合撹拌し最後にエタノールを添加し、混合撹拌し均一な点鼻組成物とした。
(処方)
(製造方法)
精製水にL-アルギニン、エデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、その混合溶液を真空撹拌装置に投入し、更に精製水にベンザルコニウム塩化物及び半量のポリソルベート80を加えて溶解した液を加え、混合撹拌した。これにあらかじめカルボキシビニルポリマーを精製水に混合溶解した液を投入した。それらを真空撹拌装置内で混合撹拌した。別に、モメタゾンフランカルボン酸エステルを濃グリセリンに湿らせ、そこに残り半量のポリソルベート80と精製水を加え、十分に撹拌し、先の撹拌混合液に投入しそれを真空撹拌装置内で混合撹拌した。必要があればpHを水酸化ナトリウム溶液または希塩酸でpH5.0に調節した後、更に高速で剪断を付加し粘度が1000mPa・sになるまで混合撹拌し最後にエタノールを添加し、混合撹拌し均一な点鼻組成物とした。
〔特許第4838493号に記載の実施例1〕
(処方)
*:結晶性セルロース・カルボキシメチルセルロースナトリウムの混合物
(製造方法)
精製水にブドウ糖を溶かしてブドウ糖溶液を調製し、これにエデト酸ナトリウム水和物を溶解した後、撹拌しながらアビセルRC591を添加し、水和させ、懸濁物Aとした。別に、50~60℃にて精製水にポリソルベート80を溶かし、フルチカゾンフランカルボン酸エステルを湿らせ、そこに残り半量のポリソルベート80と精製水を加え、懸濁物Bとした。懸濁物Aと懸濁物Bを合わせ、撹拌した。これに、精製水に溶解したベンザルコニウム塩化物を添加し、撹拌した。1N塩酸でpH6.0に調節した後、精製水を添加して重量を修正した。
〔特許第4838493号に記載の実施例1にオロパタジン塩酸塩を追加配合〕
(処方)
*:結晶性セルロース・カルボキシメチルセルロースナトリウムの混合物
(製造方法)
精製水にブドウ糖を溶かしてブドウ糖溶液を調製し、これにエデト酸ナトリウム水和物及びオロパタジン塩酸塩を溶解した後、撹拌しながらアビセルRC591を添加し、水和させ、懸濁物Aとした。別に、50~60℃にて精製水にポリソルベート80を溶かし、フルチカゾンフランカルボン酸エステルを湿らせ、そこに残り半量のポリソルベート80と精製水を加え、懸濁物Bとした。懸濁物Aと懸濁物Bを合わせ、撹拌したこれに、精製水に溶解したベンザルコニウム塩化物を添加し、撹拌した。1N塩酸でpH6.0に調節した後、精製水を添加して重量を修正した。
〔特許第5149308号に記載の実施例1〕
(処方)
(製造方法)
精製水を撹拌しながらリン酸水素二ナトリウム(無水)、塩化ナトリウム、エデト酸ナトリウム水和物、ベンザルコニウム塩化物およびオロパタジン塩酸塩を添加した。各成分の溶解のために、各適切な時間をとりながら希塩酸を適量添加した。精製水を添加し、pHを測定し、必要に応じて塩酸および水酸化ナトリウムで3.7に調節した後。精製水を添加して重量を修正した。
比較試験液検体
(1) PatanaseTM(ロット番号:7FPS1A)〔濃度pH3.8〕
製品容器から内容液を取り出し、ガラス容器に移し検体とした。
(2) オロパタジン塩酸塩を精製水に溶解して、オロパタジン濃度が0.6%(w/w)となるようにした後、L-アルギニンでpHを3.8とした液(ガラス容器に保管)
(3) オロパタジン塩酸塩を精製水に溶解して、オロパタジン濃度が0.6%(w/w)となるようにした後、水酸化ナトリウムでpHを3.8とした液(ガラス容器に保管)
(4) オロパタジン塩酸塩を精製水に溶解して、オロパタジン濃度が0.6%(w/w)となるようにした後、L-アルギニンでpHを5.5とした液(ガラス容器に保管)
(5) オロパタジン塩酸塩を精製水に溶解して、オロパタジン濃度が0.6%(w/w)となるようにした後、水酸化ナトリウムでpHを5.5とした液(ガラス容器に保管)
(1)~(5)に加えて、実施例1~実施例8、比較例1~比較例7の製剤もすべてガラス容器に充填し溶解安定性試験の検体とした。
(i)肉眼で観察する。ステロイドの微細な分散懸濁結晶とは異なる大きなオロパタジンの結晶を確認する。判断がつきにくい場合は、加温し結晶が溶解等変化した場合は、当該結晶はオロパタジンと判断する。
○:ステロイド化合物を含まない(1)~(5)および比較例3については、澄明な溶解状態と確認した。ステロイド化合物を含む実施例1~8および比較例1~2、4~7については結晶が析出していない均一な懸濁状態と確認した。
×:結晶が析出していると確認した。
(ii)デジタルマイクロスコープ(VHX-7000)を用いて500倍で確認するときステロイド以外の50μm以上の析出した結晶があるかを確認する。結晶性セルロース・カルボキシメチルセルロースナトリウムが存在し、オロパタジンの結晶と判断がつきにくい場合は、加温し結晶が溶解等変化した場合は、当該結晶はオロパタジンと判断する。
◎:ステロイド以外の結晶は確認されず、析出結晶はなく、オロパタジンは溶解していると判定した。
◆:ステロイド以外に50μm以上の析出した結晶が確認され、オロパタジンが析出したと判定した。
実施例7、比較例4、比較例5、比較例6を用いて下記試験を実施した。
(試験方法)
各試験検体(被験製剤)を十分に混合撹拌し、均一状態を維持した状態で各試験検体中のフルチカゾンフランカルボン酸エステルの含量を高速液体クロマトグラフィーで測定し、初期均一状態の完了とする(定量結果A)。
次に、均一状態の各々の試験検体12gを13.5mLガラス製スクリュー管に充填し、再度よく振とうし均一な状態とする。別に、試験検体を遠心分離(5000rpm、10分)する。
スクリュー管に充填して振とうする前後、室温で24時間放置後、1週間放置後、並びに遠心分離処理後の試験検体について、外観およびフルチカゾンフランカルボン酸エステルの含量を測定した。含量測定は、まずは各試験検体を上層3g、中層4g、残りの下層(3g)に分別し、上層と下層から試験検体を精密に2g分取し、高速液体クロマトグラフィーでフルチカゾンフランカルボン酸エステルの含量を測定する(定量結果B)。懸濁安定性は、下記の式による懸濁安定性比率を求め評価した。
懸濁安定性比率(%)=〔(定量結果B)/(定量結果A)〕×100
Claims (29)
- ステロイド化合物とオロパタジン又はその薬学的に許容できる塩とを含む医薬組成物。
- ステロイド化合物とオロパタジン塩酸塩とを含む請求項1に記載の医薬組成物。
- 粘稠剤としてカルボキシビニルポリマーを含む、請求項1または請求項2に記載の医薬組成物。
- ステロイド化合物、オロパタジンまたはその薬学的に許容できる塩、およびカルボキシビニルポリマーを含む組成物であって、その組成物のpHが4.0~7.0に調節されている請求項1~3のいずれか1項に記載の医薬組成物。
- オロパタジンまたはその薬学的に許容できる塩がオロパタジン塩酸塩であり、オロパタジン塩酸塩として0.2%(重量/重量)以上の濃度であり、オロパタジンが組成物中溶解状態で存在する、請求項1~4のいずれか1項に記載の医薬組成物。
- ステロイド化合物が0.005~1%(重量/重量)の濃度であり、ステロイド化合物が組成物中安定な分散状態で存在する、請求項1~5のいずれか1項に記載の医薬組成物。
- ステロイド化合物がベクロメタゾンプロピオン酸エステル、フルチカゾンプロピオン酸エステル、モメタゾンフランカルボン酸エステル、またはフルチカゾンフランカルボン酸エステルのいずれかである、請求項1~6のいずれか1項に記載の医薬組成物。
- ステロイド化合物がフルチカゾンフランカルボン酸エステルである請求項7の医薬組成物。
- カルボキシビニルポリマーが0.1~2%(重量/重量)の濃度で存在する、請求項1~8いずれか1項に記載の医薬組成物。
- pHを調整するために、pH調節剤として、水酸化ナトリウムおよび/または塩酸を用いる、請求項4~9いずれか1項に記載の医薬組成物。
- pHを調整するために、中和剤として、L-アルギニンを用いる、請求項4~10いずれか1項に記載の医薬組成物。
- 更に1種以上の懸濁剤を含む、請求項1~11のいずれか1項に記載の医薬組成物。
- 懸濁剤がポリソルベート80を含む、請求項12に記載の医薬組成物。
- 更に1種以上の防腐剤を含む、請求項1~13のいずれか1項に記載の医薬組成物。
- 防腐剤がベンザルコニウム塩化物を含む、請求項14の医薬組成物。
- 更に1種以上の安定化剤を含む、請求項1~15のいずれか1項に記載の医薬組成物。
- 安定化剤がエデト酸ナトリウム水和物を含む、請求項16に記載の医薬組成物。
- 更に1種以上の等張化剤を含む、請求項1~17のいずれか1項に記載の医薬組成物。
- 等張化剤が塩化ナトリウムおよび/またはグリセリンを含む、請求項18に記載の医薬組成物。
- 等張化剤が、0.1~10%(重量/重量)の濃度で存在する、請求項18または19に記載の医薬組成物。
- 等張であることを特徴とする、請求項1~20のいずれか1項に記載の医薬組成物。
- 粘度が250~2500mPa・sである、請求項1~21のいずれか1項に記載の医薬組成物。
- 噴霧した際、液滴径が30~100μmの平均液滴径を有する、請求項1~22のいずれか1項に記載の医薬組成物。
- pH調節剤が水酸化ナトリウムであり、中和剤がL-アルギニンであり、懸濁剤がポリソルベート80であり、防腐剤がベンザルコニウム塩化物であり、安定化剤がエデト酸ナトリウム水和物であり、等張化剤がグリセリンおよび塩化ナトリウムである請求項21~23のいずれか1項に記載の医薬組成物。
- pHが4.5~6.5に調整されている、請求項4~24のいずれか1項に記載の医薬組成物。
- pHが5.0~6.0に調整されている、請求項4~25のいずれか1項に記載の医薬組成物。
- 医薬組成物が点鼻用水性液剤である、請求項1~26のいずれか1項に記載の医薬組成物。
- 請求項1~27のいずれか1項に記載の医薬組成物を含む、鼻腔内投与型スプレー用製剤。
- カルボキシビニルポリマーを添加することによってオロパタジンをpH5.0~6.0の範囲で溶解する方法とフルチカゾンフランカルボン酸エステルを含む水性懸濁液を、懸濁性を安定化する方法を同時に用いて調製した医薬組成物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080092465.8A CN115279364A (zh) | 2019-12-06 | 2020-12-04 | 包含甾体化合物和奥洛他定的药物组合物 |
JP2021562756A JPWO2021112242A1 (ja) | 2019-12-06 | 2020-12-04 | |
AU2020397728A AU2020397728A1 (en) | 2019-12-06 | 2020-12-04 | Pharmaceutical composition comprising steroid compound and olopatadine |
US17/756,800 US20230000814A1 (en) | 2019-12-06 | 2020-12-04 | Pharmaceutical composition comprising steroid compound and olopatadine |
CA3160578A CA3160578A1 (en) | 2019-12-06 | 2020-12-04 | Pharmaceutical composition comprising steroid compound and olopatadine |
EP20895206.9A EP4070791A4 (en) | 2019-12-06 | 2020-12-04 | PHARMACEUTICAL COMPOSITION CONTAINING STEROID COMPOUND AND OLOPATADINE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-221421 | 2019-12-06 | ||
JP2019221421 | 2019-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021112242A1 true WO2021112242A1 (ja) | 2021-06-10 |
Family
ID=76221756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/045314 WO2021112242A1 (ja) | 2019-12-06 | 2020-12-04 | ステロイド化合物およびオロパタジンを含有する医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230000814A1 (ja) |
EP (1) | EP4070791A4 (ja) |
JP (1) | JPWO2021112242A1 (ja) |
CN (1) | CN115279364A (ja) |
AU (1) | AU2020397728A1 (ja) |
CA (1) | CA3160578A1 (ja) |
TW (1) | TW202133860A (ja) |
WO (1) | WO2021112242A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230018472A1 (en) * | 2019-12-06 | 2023-01-19 | Toko Yakuhin Kogyo Co., Ltd. | Rhinenchysis composition containing olopatadine |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4838493B1 (ja) | 1966-12-09 | 1973-11-17 | ||
JPS5149308B1 (ja) | 1971-06-16 | 1976-12-25 | ||
JPS623967B2 (ja) | 1980-09-05 | 1987-01-28 | Tokyo Shibaura Electric Co | |
JPH02264714A (ja) * | 1989-04-05 | 1990-10-29 | Toko Yakuhin Kogyo Kk | 噴霧用ゲル基剤およびそれを用いたゲル剤 |
JP2006508138A (ja) * | 2002-11-12 | 2006-03-09 | アルコン,インコーポレイテッド | アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用 |
WO2007123193A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム |
WO2007123207A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | 流体用容器およびこれを用いたエアレス式流体投与システム |
WO2011141929A2 (en) * | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
JP2016534142A (ja) * | 2013-09-13 | 2016-11-04 | グレンマーク・スペシャルティー・エスエー | モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215739A (en) * | 1989-04-05 | 1993-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
PL3468532T3 (pl) * | 2017-06-28 | 2021-06-14 | Glenmark Specialty S.A. | Urządzenie dozujące i kompozycja farmaceutyczna do leczenia nieżytu nosa |
-
2020
- 2020-12-04 WO PCT/JP2020/045314 patent/WO2021112242A1/ja unknown
- 2020-12-04 CA CA3160578A patent/CA3160578A1/en active Pending
- 2020-12-04 TW TW109142864A patent/TW202133860A/zh unknown
- 2020-12-04 US US17/756,800 patent/US20230000814A1/en active Pending
- 2020-12-04 CN CN202080092465.8A patent/CN115279364A/zh active Pending
- 2020-12-04 AU AU2020397728A patent/AU2020397728A1/en active Pending
- 2020-12-04 EP EP20895206.9A patent/EP4070791A4/en active Pending
- 2020-12-04 JP JP2021562756A patent/JPWO2021112242A1/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4838493B1 (ja) | 1966-12-09 | 1973-11-17 | ||
JPS5149308B1 (ja) | 1971-06-16 | 1976-12-25 | ||
JPS623967B2 (ja) | 1980-09-05 | 1987-01-28 | Tokyo Shibaura Electric Co | |
JPH02264714A (ja) * | 1989-04-05 | 1990-10-29 | Toko Yakuhin Kogyo Kk | 噴霧用ゲル基剤およびそれを用いたゲル剤 |
JP2006508138A (ja) * | 2002-11-12 | 2006-03-09 | アルコン,インコーポレイテッド | アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用 |
WO2007123193A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム |
WO2007123207A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | 流体用容器およびこれを用いたエアレス式流体投与システム |
WO2011141929A2 (en) * | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
JP2016534142A (ja) * | 2013-09-13 | 2016-11-04 | グレンマーク・スペシャルティー・エスエー | モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN115279364A (zh) | 2022-11-01 |
US20230000814A1 (en) | 2023-01-05 |
AU2020397728A1 (en) | 2022-06-30 |
EP4070791A1 (en) | 2022-10-12 |
JPWO2021112242A1 (ja) | 2021-06-10 |
CA3160578A1 (en) | 2021-06-10 |
EP4070791A4 (en) | 2023-11-15 |
TW202133860A (zh) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2665024C (en) | Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof | |
JP4603687B2 (ja) | 点鼻用液剤 | |
US20110008453A1 (en) | Stable Corticosteroid Nanoparticulate Formulations And Methods For The Making And Use Thereof | |
WO2007072923A1 (ja) | ステロイドの経時的安定性が改善された外用製剤 | |
CN104350063A (zh) | 疏水性治疗剂的制剂、其制备方法及应用 | |
CN101810562A (zh) | 含有皮质激素的鼻用原位凝胶 | |
WO2021112242A1 (ja) | ステロイド化合物およびオロパタジンを含有する医薬組成物 | |
JP3402195B2 (ja) | 再分散性の良い水性懸濁液剤 | |
JPWO2019235616A1 (ja) | フルチカゾンフランカルボン酸エステル点鼻組成物 | |
US11291672B2 (en) | Betamethasone oral spray formulation and method of use to treat ataxia | |
WO2021112240A1 (ja) | オロパタジンを含有する点鼻用組成物 | |
JP2020536972A (ja) | ビラスチンの水性組成物 | |
JP2009084262A (ja) | レボカバスチンとグリチルリチン酸を含有する水性医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20895206 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3160578 Country of ref document: CA Ref document number: 2021562756 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020397728 Country of ref document: AU Date of ref document: 20201204 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020895206 Country of ref document: EP Effective date: 20220706 |